Table 2.
Uveal melanoma adjuvant therapy: nonrandomized trials
| Treatment | n | Treatment eligibility | Historic controls | Result | Reference |
|---|---|---|---|---|---|
| Interferon alfa-2b 3 million units s.c., 3 times per week for 1 year | 39 | no evidence of metastasis, <2 months from primary therapy | 72 patients matched for sex, tumor localization, LTD, and tumor height | no difference in 3-year survival rate of treated (82%) vs. historic controls (90%); p = 0.27 | Richtig et al. [7], 2006 |
|
| |||||
| Interferon alfa-2a 3 million units s.c., 3 times per week for 2 years | 121 | age ≥65 years, LTD ≥15 mm, ciliary body involvement, extrascleral extension | 242 patients matched for age (±5 years), LTD (±3 mm), gender, and time between primary therapy and treatment initiation | no difference in 5-year survival rate of treated (76%) vs. historic controls (83%); p = 0.91 | Lane et al. [8], 2009 |
|
| |||||
| Fotemustine 100 mg/m2 i.a.h. weekly for 4 weeks; then every 3 weeks, 5 times | 22 | choroidal involvement, LTD >20 mm, extrascleral extension, tumor height >15 mm | 66 patients matched for clinical and tumor characteristics | no difference in 5-year survival rate of treated (75%) vs. historic controls (56%); p = 0.5 | Voelter et al. [9], 2008 |
s.c. = Subcutaneously; i.a.h. = intra-arterial hepatic; LTD = largest tumor diameter.